Citigroup Inc Vertex Pharmaceuticals Inc Put Options Transaction History

Citigroup Inc

  • $169 Billion
  • Q3 2024

Put Options

11 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$460.0 - $505.78 $7.87 Million - $8.65 Million
17,100 Added 56.81%
47,200 $22 Million
Q2 2024

Aug 12, 2024
SELL
$392.81 - $485.53 $12.8 Million - $15.8 Million
-32,600 Reduced 51.99%
30,100 $14.1 Million
Q1 2024

May 10, 2024
SELL
$407.69 - $446.08 $11.3 Million - $12.4 Million
-27,800 Reduced 30.72%
62,700 $26.2 Million
Q4 2023

Feb 09, 2024
BUY
$343.0 - $410.68 $12.1 Million - $14.5 Million
35,300 Added 63.95%
90,500 $36.8 Million
Q3 2023

Nov 09, 2023
BUY
$338.18 - $362.46 $11.7 Million - $12.6 Million
34,700 Added 169.27%
55,200 $19.2 Million
Q2 2023

Aug 10, 2023
BUY
$314.42 - $351.91 $6.45 Million - $7.21 Million
20,500 New
20,500 $7.21 Million
Q4 2022

Feb 09, 2023
SELL
$285.76 - $321.48 $4.29 Million - $4.82 Million
-15,000 Reduced 55.56%
12,000 $3.47 Million
Q3 2022

Nov 10, 2022
BUY
$273.83 - $305.53 $2.79 Million - $3.12 Million
10,200 Added 60.71%
27,000 $7.82 Million
Q2 2022

Aug 10, 2022
SELL
$234.96 - $292.55 $27.8 Million - $34.6 Million
-118,400 Reduced 87.57%
16,800 $4.73 Million
Q1 2022

May 12, 2022
BUY
$221.42 - $260.97 $28.4 Million - $33.5 Million
128,200 Added 1831.43%
135,200 $35.3 Million
Q3 2021

Nov 10, 2021
BUY
$181.39 - $202.99 $1.27 Million - $1.42 Million
7,000 New
7,000 $1.27 Million

Others Institutions Holding VRTX

# of Institutions
1,724
Shares Held
221M
Call Options Held
1.58M
Put Options Held
1.36M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email